Israeli scientists have introduced a groundbreaking vaccine that shows complete effectiveness against a deadly bacteria. Tel Aviv University, in collaboration with the Israel Institute for Biological Research, has developed this mRNA-based vaccine, a first of its kind to target bacteria. Professor Dan Peer from Tel Aviv University shared with Fox News Digital that the vaccine offers “100% protection against pneumonic plague,” which is known to be the deadliest manifestation of the disease.
Yersinia pestis, the bacteria responsible for the plague, is notoriously lethal even in small amounts and is classified by the CDC as a “Tier 1 select agent” due to its potential use in bioterrorism. Professor Peer, along with Dr. Inbal Hazan-Halefy and PhD student Shani Benarroch, has made significant strides in combating this threat. Recent natural outbreaks have highlighted the ongoing risk posed by Y. pestis, emphasizing the need for an effective vaccine.
The researchers tested their innovative mRNA vaccine on animals infected with the bacteria, as detailed in a university press release. The results were promising; within a week, unvaccinated animals succumbed to the disease, while those vaccinated remained healthy. The study, published in Science Advances, reinforces the vaccine’s potential in providing full protection after just one dose.
Before this breakthrough, mRNA vaccines were only effective against viruses, such as COVID-19, and not against bacteria. Dr. Edo Kon of Tel Aviv University explained that the scientific community previously believed mRNA vaccines couldn’t target bacteria. However, their study successfully demonstrated that mRNA vaccines can indeed be “100% effective against deadly bacteria.”
While traditional vaccines for viruses work by prompting human cells to produce viral proteins to train the immune system, this method wasn’t as effective for bacteria. The team employed a new strategy, introducing bacterial proteins in a way that elicited a strong immune response. They enhanced the stability of the bacterial protein by pairing it with a segment of human protein, achieving a comprehensive immune reaction.
Dr. Jacob Glanville, CEO of Centivax, echoed the significance of these findings. He pointed out that this research extends the applications of mRNA technologies beyond areas like coronavirus and flu vaccines. He also noted the scrutiny mRNA vaccines have faced following COVID-19, stressing the importance of applying lessons learned to future vaccine developments.
There are some limitations to the study, as the vaccine’s effectiveness has only been demonstrated in mice. Professor Peer emphasized the need for clinical trials to evaluate the vaccine’s effectiveness in humans. Moreover, the experimental vaccine relies on the “lipid nanoparticle (LNP) mRNA vaccine platform,” which requires a cold storage chain, although efforts are underway to optimize storage conditions.
This vaccine could potentially expedite the development of vaccines for other bacterial diseases, especially those that are antibiotic-resistant. The overuse of antibiotics has led to resistant bacteria, posing a significant threat to human health. A new vaccine approach could address this global issue.
Professor Peer noted that the rapid development of the COVID-19 vaccine was built on years of mRNA research, suggesting that a similar approach could be applied to bacterial pandemics. The study, supported by various institutions, marks a step forward in preparing for future health challenges.
In conclusion, the research offers a promising new avenue for mRNA vaccines, potentially paving the way for addressing antibiotic resistance and improving global health security. The study was made possible with support from the European Research Council, the Israel Institute for Biological Research, and the Shmunis Family Foundation.
